|
|
Investment Summary
- Imagenetix has an experienced management team with a proven track
record in the public market and with natural-based products.
- Management is focused on creating value for shareholders by pursuing
existing and well-defined multi-billion dollar markets. Almost all
of the Company’s products will be competing in the nutritional
and skin care arena, markets that are growing.
- For select Imagenetix products that may qualify for drug development,
the Company will seek to patent protect the products and create the
necessary science.
- They are accomplishing this through effective products, research,
clinical studies, top-notch professionals, and presentations of their
science to appropriate conferences and peer reviewed journals.
- Celadrin®, the Company’s lead, proprietary, natural-based
product, is a scientifically tested product developed to provide support
for healthy joint function and mobility. This creates an opportunity
in a multi-billion dollar market for Imagenetix to create significant
sales as product recognition develops.
- The Company has a core group of natural-based, proprietary, bioceutical
products and formulations that are in various stages of scientific
development or in early stages of being marketed.
- Each product addresses markets that are in high demand.
- Through its proprietary Globestar® System, Imagenetix provides
a timely and comprehensive global business to business intranet solution
to its foreign distributors as well as to its domestic clients.
- In its first few years of operations, Imagenetix has been diligent
in creating product value, science, and distributors from which to
launch the Company and its products while at the same time remaining
fiscally responsible.
- The Company expects rapid growth as consumers become exposed to product
information that will be forthcoming through scientific releases, conferences,
papers, business and industry articles, celebrity endorsements, ads,
media, and distributor marketing of the products.
- The Company is in the early stages of conducting clinical trials
for its pharmaceutical compound, Genepril, to treat periodontal disease.
|
